Tags » People Places Events

Amarin Says It Will Complete Cardiovascular Outcomes Trial For Its Fish Oil Pill

After nearly a year of uncertainty, Amarin  announced  its commitment to complete REDUCE-IT  (Reduction of Cardiovascular Events with EPA – Intervention Trial). The trial is designed to test the effects on cardiovascular outcomes of Vascepa, the company’s high EPA omega-3 prescription fish oil product, in people with moderately elevated triglyceride levels between 200-499 mg/dL. 40 more words

Policy & Ethics

Japanese Research Scandal Involving Novartis Blood Pressure Drug Widens

The Japanese scandal over research using the Novartis blockbuster hypertension drug Diovan (valsartan) continues to widen. The first major figure brought down in the scandal was  90 more words

Policy & Ethics

FDA Approves New Weight Loss Drug From Orexigen And Takeda

The FDA announced today that it had approved Contrave, the long-awaited and much-disputed weight loss drug.  The drug is a combination of two drugs already approved for other indications: naltrexone hydrochloride, which is used to combat alcohol and opioid dependence, and bupropion, which is used to treat depression and seasonal affective disorder and as an aid to smoking cessation treatment. 21 more words

Policy & Ethics

FDA Advisory Panel Offers Cautious Support For Polypill

The controversial polypill took one step closer to reaching the US market after receiving a mostly positive reception from the FDA’s Cardiovascular and Renal Drugs Advisory Committee on Wednesday. 115 more words

Beyond Kickbacks: More Questions About Unnecessary Cardiovascular Tests

On the front page of the Wall Street Journal today is an important story about a fast-growing company accused of giving kickbacks to physicians who order the company’s tests measuring a wide variety of cardiovascular biomarker tests. 93 more words

Policy & Ethics

Newly Elected European Society Of Cardiology President Co-Authored Hundreds Of Papers With Don Poldermans

The ESC today announced that Jeroen Bax, a Dutch cardiologist, will serve as the group’s President Elect for the next two years before becoming President starting in 2016. 51 more words

Policy & Ethics

Early Hint At Cardiovascular Outcomes With Sanofi's and Regeneron's Rapidly Advancing Cholesterol Drug

Amid a slew of new data demonstrating yet again that PCSK9 inhibitors lower LDL cholesterol– drastically and in a wide variety of different patient populations– data from one trial offers the first suggestion that the drugs may in fact improve cardiovascular outcomes. 74 more words

Policy & Ethics